1 / 34

Challenges in Managing BKP Virus in Renal Transplantation

Challenges in Managing BKP Virus in Renal Transplantation. BKP Infection and RT. Clin J Am Soc Nephrol 2007;2: S36–S46,. Polyomavirus infection in kidney transplant recipients is of increasing interest and research

roland
Download Presentation

Challenges in Managing BKP Virus in Renal Transplantation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Challenges in Managing BKP Virus in Renal Transplantation

  2. BKP Infection and RT Clin J Am Soc Nephrol 2007;2: S36–S46, Polyomavirus infection in kidney transplant recipients is of increasing interest and research Nephropathy from BK virus infection is an evolving challenge in kidney transplant recipients It is the consequence of modern potent immunosuppression aimed at reducing acute rejection and improving allograft survival Untreated BKV infections lead to kidney allograft dysfunction or loss

  3. Type and prevalence of BKV infections inkidney transplant recipients Clin J Am Soc Nephrol 2007;2: S36–S46,

  4. BK Polyomavirus

  5. BK Polyomavirus JC virus (agent of progressive multifocal leukoencephalopathy) and SV40 in same family Common viral infection with latency in uroepithelium, and in other tissues Associated with sterile pyuria, ureteral ulceration and obstruction, hemorrhagic cystitis, parenchymal scarring in renal transplant recipients—rise in serum creatinine termed “BK nephropathy” Causes hemorrhagic cystitis in BMT/HSCT; asymptomatic viruria in 10% to 45% of renal transplant recipients; disease (BK nephropathy) in 2% to 4% of all renal transplant recipients, but uncommon in extrarenal transplant recipients • BMT, bone marrow transplant; HSCT, hematopoietic stem cell transplantation. • Binet I et al. Transplantation. 1999;67:918-922; McGilvray ID et al. Am J Transplant. 2003; 3:501-504; Nickeleit V et al. J Am Soc Nephrol. 1999;10:1080-1089.

  6. BK Nephropathy 50% of BK nephritis in first 3 months posttransplantation May coexist with rejection—may be exacerbated by corticosteroid boluses (possible role of corticosteroid- responsive element in promoter) Linked to intensity of immune suppression (not specific agents) Mylonakis E et al. Transplantation. 2001;72:1587-1592; Drachenberg RC et al. Am J Transplant. 2001;1:373-381; Gardner SD, et al. J Clin Pathol. 1984; 37:578-586; Ramos E, et al. J Am Soc Nephrol 2002; 13:2145-2151.

  7. A typical tubular cell infected by polyoma virus BK

  8. BK Virus: Diagnosis Urine cytology is highly sensitive (but not specific) for screening: urine decoy cells (cytology) Tissue biopsy needed for confirmation Histology: tubular injury, cellular enlargement, inflammation, intranuclear and intracytoplasmic inclusion bodies (exclude rejection, PTLD) Electron microscopy: intracellular crystalline arrays Nucleic acid hybridization in situ PCR (blood): higher incidence of viremia in symptomatic patients; many asymptomatic – but not diagnostic Urine cellular PCR (VP1 mRNA): 6 x 105 copies/ng1 PTLD, posttransplant lymphoproliferative disorder; PCR, polymerase chain reaction, 1. Ding R et al. Transplantation. 2002;74:987-994.

  9. Urine cytology

  10. Urine cytology

  11. BK Virus: Mononuclear Infiltrate With Nuclear Inclusions Renal allograft biopsy 9 months post–deceased-donor transplantation demonstrating BK nephropathy

  12. BK Virus: Immunoperoxidase Stain for SV-40 Large T Antigen

  13. Noninvasive tests for BKV nephropathya Clin J Am Soc Nephrol 2007;2: S36–S46,

  14. Immunohistochemistry shows characteristic nuclear staining isolated to the medulla

  15. Histologic patterns of BKV nephropathy Clin J Am Soc Nephrol 2007;2: S36–S46,

  16. BK Virus: Therapy No specific therapy at present Reduction in immune suppression results in graft loss of 16.4% to 80%; many maintain serum creatinine levels at ~2.5 mg/dL Low-dose cidofovir has anecdotal successes andfailures but may cause renal dysfunction Some anecdotal experience with leflunomide (unapproved, no prospective trials), an immunosuppressive agent for rheumatologic disease with antiviral activity for BK and herpesviruses Some anecdotal experience with later-generation fluoroquinolones Ramos E et al. Transplantation. 2004;77:131-133; Vats A et al. Transplantation. 2003; 75:105-112; Poduval RD et al. Transplantation. 2002;73:1166-1169.

  17. Treatment Strategies • The principal treatment for BKV nephropathy is reduction in immunosuppression. • Various strategies include reduction or discontinuation of the calcineurin inhibitor and/or adjuvant agent, changing from MMF to azathioprine, sirolimus, or leflunomide or from tacrolimus to cyclosporine • Importantly, BKV nephropathy seems to develop less frequently with maintenance protocols that involve steroid withdrawal • When BKV nephropathy is diagnosed early within the first 6 mo after transplantation and the creatinine is stable, survival is improved compared with when the diagnosis is made later and the creatinine is elevated. Daniel L. et al. Clin J Am Soc Nephrol 2007;2: S36–S46

  18. Early or Presumptive BKV Nephropathy • Reduction in immunosuppression to clear the infection is balanced against the risk for precipitating acute or chronic rejection • Preemptive withdrawal of the antimetabolite upon detection of viremia prevents BKV nephropathy without significantly increasing the risk for rejection. • A step-wise reduction in MMF plus reduction in tacrolimus or conversion to cyclosporine. Brennan DC et al Am J Transplant 5: 582–594, 2005, Buehrig CK et al. Kidney Int 64: 665–673, 2003,

  19. Impaired immune suppression balance. Inadequate immune suppression results in rejection, whereas excessive immune suppression results in BKV nephropathy. Both conditions present as allograft dysfunction with tubulointerstitial nephritis and progression to fibrosis.

  20. Late BKV Nephropathy • Diagnosis of BKV nephropathy in the setting of allograft dysfunction often indicates more severe histologic changes, and renal function may only stabilize or may continue to progress despite treatment • Also, not treating or inadvertently treating with an antilymphocyte antibody often will lead to progression of disease (96). • Whether to reduce or discontinue one or more components of the maintenance regimen is not clear • No difference in graft survival whether immunosuppression wasreduced or continued or between reduction and discontinuation of tacrolimus or MMF among recipients with BKV nephropathy Daniel L. et al. Clin J Am Soc Nephrol 2007;2: S36–S46

  21. Adjuvant Therapies • On the basis of in vitro activity against BKV, treatment options for BKV nephropathy are • cidofovir, • quinolones, and • intravenous Ig (IVIG) Daniel L. et al. Clin J Am Soc Nephrol 2007;2: S36–S46

  22. Cidofovir • Cidofovir, a cytosine analogue and viral DNA polymerase inhibitor, inhibits BKV replication, mechanism is unclear • Cidofovir restores the function of p53 and pRB, targets of the large T antigen, and permit BKV-infected cells to undergo apoptosis • Cidofovir dose range for BKV nephropathy : 0.25 to 1 mg/kg every 1 to 3 wk • Cidofovir is used in conjunction with immunosuppression reduction • Cidofovir should be used with caution, frequent monitoring, and informed consent because of the potential complications De Clercq E.Clin Microbiol Rev 16: 569–596, 2003 , Daniel L. et al. Clin J Am Soc Nephrol 2007;2: S36–S46

  23. Quinolones • Quinolones, DNA gyrase inhibitors • Interfere with the large T antigen helicase activity and have in vitro and in vivo activity against BKV (112–114). • Two months after a 10-d course of gatifloxacin, seven of 10 recipients with active BKV replication had reduction in viremia or urinary decoy cells • Thamboo et al. did not find improvement in viral clearance after a 10-d course of ciprofloxacin. Leung AY et al Clin Infect Dis 40: 528–537, 2005, Randhawa PS et al Clin Infect Dis 41: 1366–1367, 2005, Chandraker A et al. Am J Transplant 4: 587, 2004, Stenlund A et al Nat Rev Mol Cell Biol 4: 777–785, 2003, Thamboo TP et al . J Clin Pathol December 8, 2006

  24. IVIG • IVIG has been used for treatment for BKV nephropathy because of its immunomodulatory as well as potential anti-BKV properties • In combination with immunosuppression reduction, IVIG (2 to 3.5 g/kg over 2 to 7 d) treatment used as initial treatment for BKV nephropathy and BKV nephropathy with concurrent acute rejection • Because of the cost potential adverse effects and unproven efficacy, IVIG use for BKV nephropathy should be limited until controlled studies suggest benefit Cibrik DM et al Am J Transplant 3:370, 2007, Sener A et al. Transplantation 81: 117–120, 2006, Jordan SC et al Am J Transplant 6: 459–466, 2006, Orbach H et al. Clin Rev Allergy Immunol 29: 173–184, 2005

  25. Screening • It is recommended that screening for BKV should be performed every 3 mo for the first 2 yr after transplantation,then annually through the fifth year, when allograft dysfunction occurs and when a transplant kidney biopsy is performed • Screening should be based on a urinary assay for decoy cells, BKV DNA, or BKV RNA. A positive screening test should be confirmed within 4 wk along with a quantitative assay. • Recipients with persistent high viral levels for 3 wk should undergo biopsy and intervention. • Monitoring should continue every 2 to 4 wk until the viral level falls below threshold values and preferably to undetectable levels. Daniel L. et al. Clin J Am Soc Nephrol 2007;2: S36–S46

  26. Screening protocol based on plasma BKV DNA PCR Daniel L. et al. Clin J Am Soc Nephrol 2007;2: S36–S46

  27. Conclusion-1 • BKV nephropathy remains a significant posttransplantation complication. • Modern potent immunosuppressive medications have reduced acute rejection rates, improved early kidney allograft survival, and expanded the potential transplant population. • For an individual recipient, however, the increased immunosuppression may be excessive and predispose to BKV nephropathy • No clinical risk factors clearly identify the recipients who will develop BKV nephropathy.

  28. Conclusion-2 • BKV infection is an area of active investigation in kidney transplantation, much of the data are derived from retrospective case-control studies. • Prospective, randomized studies to address immunosuppression protocols, immune monitoring for BKV-specific and allospecific responses, and treatment protocols are needed. • Until reliable measures of immunosuppression or novel agents that specifically target BKV are available, BKV infections in kidney transplantation will remain a challenge

More Related